Our Mission is to extend healthy longevity through innovative AI solutions for drug discovery and aging research.
We aspire to be a leader in the field of deep learning for drug discovery, personalized healthcare, and anti-aging interventions.
AI Pharma Pipeline
We developed a comprehensive drug discovery engine, which utilizes millions of samples and multiple data types to discover signatures of disease and identify the most promising targets for billions of molecules that already exist or can be generated
de novo with the desired set of parameters.
Integrated top-down and bottom-up target ID
and drug discovery pipelines
Pharmaceutical Pipeline Leads
Nutraceutical Pipeline Leads
Services & Collaborations
We provide services to academia, pharmaceutical and cosmetics companies:
  • Advanced deep learning solutions
  • Custom drug discovery engines
  • Custom biomarkers discovery
  • New tools for aging research
Bridging the pharmaceutical
and consumer industries
Awards & Recognition
We will provide customers with the industry-leading services, based
on our extensive experience and proven track-record in innovative
computational technology
Nvidia Top 5
AI Companies for Social Impact
Nvidia GTC 2015 Finalist
Deep Learning for Drug Discovery
Most Promising Company
at the Personalized Medicine World Conference 2015 in Palo Alto, CA
106 Artificial Intelligence Startups In Healthcare
From Virtual Nurses To Drug Discovery: 106 Artificial Intelligence Startups In Healthcare
Videos about Insilico Medicine
Two Minute Papers: Insilico Medicine
About Insilico Medicine
Geroprotect Partnership Between Life Extension and Insilico Medicine
Chemistry AI
Some of Our Current Projects
Insilico Medicine is committed to transforming the pharmaceutical industry with next-generation artificial intelligence.
We are developing new tools for drug discovery and repurposing, biomarker development and pursuing novel strategies
for rapid validation. Our projects combine advances in genomics, big-data analysis, deep learning and reinforcement learning.
Over 150 Academic
and Industry Collaborators Worldwide

We have a great pleasure to work with the leading companies and institutions
to provide next-level solutions for drug discovery and biomarker development.
Our News
Check out our latest news.

Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specialized in the application of deep learning for target identification, drug discovery and aging research, announced that it has entered into a collaboration agreement with WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company.

A ranking of the 100 most promising private artificial intelligence companies in the world

Insilico Medicine collaborates with Neuromation. The recent collaboration on the 3D representations of the molecular structures for GANs.

Insilico Medicine, a company specializing in the application of next-generation artificial intelligence for drug discovery, biomarker development and aging research, announces the presentation of its CEO, Alex Zhavoronkov, at the Pioneers 18 Conference, May 25, 2018, Vienna, Austria.

Insilico Medicine announces the presentation of its Africa AI, Blockchain and Longevity Consultant, Iraneus Ogu, at the KMA 46th Annual Scientific Conference, April 21, 2018, Mombasa, Kenya.

Oct. 30, 2017, London, UK: Biogerontology Research Foundation ( Chief Science Officer, Dr. Alex Zhavoronkov and Biogerontology Research Foundation Advisor and Head of Business Development for Juvenescence …

Insilico Medicine, a leader in the field of artificial intelligence, will present at the Singularity University Exponential Medicine Program in San Diego on Wednesday November 8 in Session XVIII - Future of Pharma

Insilico Medicine will present at The World Congress on Targeting Metabesity in London, UK on Tuesday, Oct. 31 in Session VIII: Are New Business Models Needed?

Our team is formed of bioinformatics, computational and structural biology experts, experienced medicinal chemists and deep learning engineers, who work with massive biomedical data and practical problems in drug discovery.
Alex Zhavoronkov, PhD
Qingsong Zhu, PhD
Alex Aliper, PhD
President of EMEA
Marine Bozdaganyan,
Head of Medicinal Chemistry
Ivan Ozerov,
Director, Drug Discovery
Quentin Vanhaelen, PhD
Director, Virtual Human Project
Jimmy Yen-Chu Lin, PhD
Chief Science Officer Insilico Taiwan
Artur Kadurin
Chief of AI / CEO Insilico Taiwan
Elizabeth Cha,
Country Manager Insilico Taiwan
Alex Zhebrak
Chief Technology Officer
Polina Mamoshina
Head of Biomarker Development
Emmanuel Salawu,
Head of Deep Learning, Taiwan R&D Office
We have 45 scientists hired through hackathons and competitions worldwide in the US, UK, Poland, Belgium, South Korea, Taiwan, Africa and Russia.
Scientific Advisory Board
Charles Cantor, PhD
ex-Director of the Human Genome Project and the Center for Advanced Biotechnology at Boston University
Michael Levitt, PhD
2013 Nobel Laureate (Chemistry) Professor, Stanford University
Bud Mishra, PhD
Professor of computer science at Courant Institute, professor of biology at Mt. Sinai School of Medicine and NYU School of Medicine
Donald Small, MD, PhD
Director of pediatric oncology at the Johns Hopkins Kimmel Cancer Center
Yuri Nikolsky, PhD
Co-founder, GeneGo, ex-VP Thomson Reuters Director, Skolkovo Found
Kristen Fortney, PhD
CEO, BioAge.
Postdoctoral fellow of Ellison Medical Foundation/American Federation for Aging Research at Stanford University
Alexey Moskalev, PhD
Professor at Syktyvkar State University
Head of the laboratory of Molecular radiobiology and gerontology at the Institute of biology of Komi Science Center of Ural division of RAS
Ulrich Muehlner, PhD
Founder at GrowthCube Partners
Previously Director Global Corporate Strategy at Novartis and with The Boston Consulting Group (BCG)
Molecular Pharmaceutics, 23 March 2018
Our Publications
Special issue in American Chemical Society's Molecular Pharmaceutics mostly dedicated to GANs and molecules
Generative adversarial networks and deep reinforcement learning techniques are propagating into the many areas of pharmaceutical R&D, learning and augmenting human abilities.
Upcoming Conferences
Nature Conference Ageing, Health & Rejuvenation
June 23-26, 2019 | Netherlands
Conference Website
Health Horizons Forum
June 26-27, 2019 | Cambridge, UK
Conference Website
Basel Life 2019
September 9-12, 2019 | Basel, Switzerland
Conference Website
6th Annual Aging, Drug discovery & Artificial Intelligence Forum
September 10-12, 2019 | Basel, Switzerland
Conference Website
2019 Annual Meeting of the American College of Clinical Pharmacology
September 15-17, 2019 | Chicago, USA
Conference Website
3rd Annual Artificial Intelligence in Drug Development Congress
September 25-26, 2019 | London, UK
Conference Website
XPOMET© Medicinale 2019
October 10-12, 2019 | Berlin, Germany
Conference Website
AI World Conference&Expo
October 23-25, 2019 | Boston, USA
Conference Website
HLTH Create Health's Future
October 27-30, 2019 | MGM Grand, Las Vegas
Conference Website
International Symposium Biology of Aging: Understanding Aging to Better Intervene
November 9-11, 2019 | Montreal, Canada
Conference Website
BioDataWorld Congress 2019
December 4-5, 2019 | Basel, Switzerland
Conference Website
Press About Us
June 12, 2018

AI And Biotech Companies In The East And West Invest In Combating Aging
Insilico Medicine, a Baltimore-based next-generation AI company specializing in the application of deep learning for target identification, drug discovery and aging research, yesterday announced a collaboration agreement with WuXi AppTec...
Read more
April 23, 2017

Nvidia identifies the top 5 AI startups for social impact
Nvidia is on a quest to find the best "social impact" artificial intelligence startups as part of a program called Nvidia Inception, which is screening more than 600 entrants to cull the best AI startups in three big categories.
Read more
Contact us:
Insilico Medicine

Rm 8, Unit 111-113
ICT Co-Working Centre
1/F Enterprise Place,
5 Science Park West Avenue, Hong Kong